Neoadjuvant chemotherapy with Ifosfamide and Cisplatin combination in advanced head and neck cancer: a retrospective analysis of 519 patients: a single institution experience
In Medical Oncology
Contributor(s): Parikh PM | Mistry RC | Bakshi AV | Parikh DM | Mazumdar, Alaka T | Deshmukh C | Pathak KA | drvrpai@rediffmail.com | Pai VR.
Material type:
Item type | Current location | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|
![]() |
Tata Memorial Hospital | Available | AR4526 |
Advanced head and neck cancer is a major therapeutic problem in India. Ifosfamide has shown significant activity as a single agent in head and neck squamous carcinoma. In this study, we present our experience with two cycles of ifosfamide and cisplatin in the neoadjuvant setting given to a total of 519 patients. The complete response rate was 20% and the overall response rate was 80%. The treatment was well tolerate, there was no need for dose reduction, and there were no life-threatening side effects. We feel that this high response rate is sufficient to warrant more studies using ifosfamide-based combinations in a neoadjuvant setting for squamous carcinoma of the head and neck.
There are no comments for this item.